Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PHASE II, OPEN LABEL, SINGLE DOSE STUDY OF THE SAFETY AND EFFICACY OF MNV-201 FOR THE TREATMENT OF PEARSON SYNDROME

NCT06017869 is registered in ClinicalTrials.gov with Minovia Therapeutics Ltd. as lead sponsor.

NCT NCT06017869
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06017869 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PHASE II, OPEN LABEL, SINGLE DOSE STUDY OF THE SAFETY AND EFFICACY OF MNV-201 FOR THE TREATMENT OF PEARSON SYNDROME
Lead sponsor
Minovia Therapeutics Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
July 31, 2023
Completion date
December 31, 2028
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mitochondrial diseases, pearson syndrome